CAMBRIDGE, Mass., April 25, 2018 – Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced that it has initiated dosing of the first patient in each of two clinical studies evaluating DSP-7888, an investigational cancer peptide vaccine. One study is in combination with checkpoint inhibitors for multiple tumor types, and the other is in combination with bevacizumab in glioblastoma. DSP-7888 is hypothesized to induce Wilms’ tumor gene 1 (WT1)-specific cytotoxic T lymphocytes (CTL) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic cancers and solid tumors. WT1 has been a focus of cancer vaccine researchers since the National Cancer Institute ranked it as the number one priority target for cancer immunotherapy.[i]
“Despite significant advances in cancer treatment, there remains a need for new, effective treatment options for many patients,” said Patricia S. Andrews, Chief Executive Officer, Boston Biomedical, Inc. “We are exploring the potential of DSP-7888 to elicit an anti-tumor response in a number of high unmet need tumor types.”
The multicenter, open-label, phase 1b study of DSP-7888 in combination with checkpoint inhibitors, known as WIZARD101CI, is targeted to enroll approximately 84 patients who will receive either DSP-7888 in combination with nivolumab or in combination with
The multicenter, global phase 2 study of DSP-7888 in combination with bevacizumab in glioblastoma, known as WIZARD201G, is targeted to enroll approximately 200 patients with recurrent or progressive glioblastoma following treatment with first-line therapy consisting of surgery and radiation with or without chemotherapy. Patients will receive either DSP-7888 in combination with bevacizumab or bevacizumab alone. The primary endpoint of the study is OS, with secondary endpoints including survival at 12 months, PFS at six months, median PFS, response rate (complete response + partial response), duration of response, and adverse event profile. Further information about this study is available at www.ClinicalTrials.gov (NCT03149003).
DSP-7888 is also being investigated in early phase studies in patients with pediatric
DSP-7888 is an investigational cancer peptide vaccine containing peptides that induce WT1-specific CTL and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic and solid tumors. Researchers have identified that by adding helper T
DSP-7888 is currently being investigated in three monotherapy studies: a phase 1/2 study in myelodysplastic syndrome (MDS) (NCT02436252), a phase 1/2 study in pediatric patients with relapsed or refractory
About Boston Biomedical, Inc.
Boston Biomedical, Inc. was founded in
Additional information about the company and its pipeline can be found at www.BostonBiomedical.com.
Disclaimer Regarding Forward-Looking Statements
The forward-looking statements in this press release are based on management’s assumptions and beliefs in light of information presently
For general inquiries:
Boston Biomedical, Inc.
For media inquiries:
SOURCE Boston Biomedical, Inc.
[i] Cheever, M., Allison, J.P., Ferris, A.S., Finn, O.J., Hastings, B.M., Hecht, T.T. (2009) The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clinical Cancer Research. http://clincancerres.aacrjournals.org/content/15/17/5323.full-text.pdf. Accessed April 2018.
[ii] Goto, M., Nakamura, M., Suginobe, N., Takasu, H., Takanashi, Y., Ban, H. and Li, C. (2016) DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1. Blood. http://www.bloodjournal.org/content/128/22/4715. Accessed April 2018.